Aditxt, Inc., a biotech company, has announced amendments to its merger agreement with Evofem Biosciences, Inc. through a Current Report on Form 8-K filed with the SEC. The report, dated September 6, 2024, details the company's entry into Amendment No. 2 to the Amended and Restated Merger Agreement. This amendment adjusts the dates and amounts of the third and fourth equity investments Aditxt is making in Evofem. The third investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. The fourth investment date has been extended from September 30, 2024, to October 31, 2024, with the amount increased from $1 million to $1.5 million. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report also includes a cautionary note on forward-looking statements and clarifies that this is not an offer to sell securities or a solicitation of an offer to buy any securities.

Aditxt, Inc., a biotech company, has announced amendments to its merger agreement with Evofem Biosciences, Inc. through a Current Report on Form 8-K filed with the SEC. The report, dated September 6, 2024, details the company's entry into Amendment No. 2 to the Amended and Restated Merger Agreement. This amendment adjusts the dates and amounts of the third and fourth equity investments Aditxt is making in Evofem. The third investment date has been changed from September 6, 2024, to September 30, 2024, with the investment amount reduced from $2 million to $1.5 million. The fourth investment date has been extended from September 30, 2024, to October 31, 2024, with the amount increased from $1 million to $1.5 million. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The report also includes a cautionary note on forward-looking statements and clarifies that this is not an offer to sell securities or a solicitation of an offer to buy any securities.